Tyler Heeren, MD
Internal Medicine · Las Vegas, NVNPI 1942735808
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Mimedx Group, Inc. accounts for 62.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $1,105 and has fallen 83.2% since, to $185 in 2025.
Across 24 payments — averaging $61.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$924
- Kerecis Limited$182
- W. L. Gore & Associates, Inc.$93
- Smith+Nephew$77
- Organogenesis Inc.$70
- AbbVie$56
- plus $75 from 3 others
What the payments were for
- Food & beverage$1,478100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mimedx Group, Inc. | 7 | $924 |
| Kerecis Limited | 4 | $182 |
| W. L. Gore & Associates, Inc. | 1 | $93 |
| Smith+Nephew | 5 | $77 |
| Organogenesis Inc. | 1 | $70 |
| AbbVie | 2 | $56 |
| Urgo Medical North America, LLC | 2 | $38 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Amgen | 1 | $16 |
How this compares
$1,478 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 100 | $4,323 |
| Mupirocin | 208 | $1,606 |
| Linezolid | 19 | $868 |
| Doxycycline Hyclate | 64 | $504 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 34 | $365 |
| Nystatin | 20 | $289 |
| Levofloxacin | 38 | $167 |
| Cephalexin | 16 | $100 |
| Ciprofloxacin Hcl | 18 | $60 |
| Amoxicillin | 11 | $28 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Las Vegas
- Kevin DunsmoorLas Vegas$241K
- Robert ChiascioneLas Vegas$174K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
- Audrey Sue CruzLas Vegas$34K
- Bashab BanerjiLas Vegas$26K
- Amaan ShafiLas Vegas$25K
- Sassan KavehLas Vegas$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.